Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19952711 | 0.83 | L3MBTL1 (0.40) | L3MBTL1CYP1A2CYP2C19POLBMEN1 | |
| SCHEMBL807773 | 0.76 | SLC6A2 (0.59) | CYP1A2CYP2C19CYP3A4SLC6A2SLC6A4 | |
| SCHEMBL5845283 | 0.73 | CRHR1 (0.48) | — | |
| SCHEMBL4441083 | 0.72 | SLC6A2 (0.64) | L3MBTL1CYP1A2CYP2C19CYP3A4SLC6A2 | |
| SCHEMBL13749562 | 0.70 | CYP1A2 (0.62) | L3MBTL1CYP1A2CYP2C19CYP3A4SLC6A2 | |
| SCHEMBL10702984 | 0.70 | CYP1A2 (0.58) | CYP1A2CYP2C19CYP3A4SLC6A2SLC6A4 | |
| SCHEMBL13236112 | 0.70 | SLC6A2 (0.60) | CYP1A2CYP2C19CYP3A4SLC6A2SLC6A4 | |
| SCHEMBL8936827 | 0.69 | HTT (0.67) | L3MBTL1CYP1A2CYP2C19CYP3A4SLC6A2 | |
| SCHEMBL8936775 | 0.68 | SLC6A2 (0.55) | L3MBTL1CYP1A2CYP2C19CYP3A4SLC6A2 | |
| SCHEMBL15242475 | 0.67 | SLC6A2 (0.67) | CYP1A2CYP2C19CYP3A4SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3510029-B1 | ALLOSTERIC CORTICOTROPIN-RELEASING FACTOR RECEPTOR 1 (CRFR1) ANTAGONISTS THAT DECREASE P-TAU AND IMPROVE COGNITION | UNIV CALIFORNIA (US) | 2025-11-05 | — | — | EP | disclosed |
| CN-109906222-B | Allosteric corticotropin releasing factor receptor 1 (CRFR 1) antagonists that reduce P-TAU and improve cognition | 加利福尼亚大学董事会 | 2023-08-01 | — | — | CN | disclosed |
| US-11077108-B2 | Allosteric corticotropin-releasing factor receptor 1 (CRFR1) antagonists that decrease p-tau and improve cognition | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-08-03 | — | — | US | disclosed |
| US-11077108-B2 | Allosteric corticotropin-releasing factor receptor 1 (CRFR1) antagonists that decrease p-tau and improve cognition | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-08-03 | — | — | US | disclosed |
| US-20190307747-A1 | ALLOSTERIC CORTICOTROPIN-RELEASING FACTOR RECEPTOR 1 (CRFR1) ANTAGONISTS THAT DECREASE P-TAU AND IMPROVE COGNITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-10-10 | — | — | US | disclosed |
| US-20190307747-A1 | ALLOSTERIC CORTICOTROPIN-RELEASING FACTOR RECEPTOR 1 (CRFR1) ANTAGONISTS THAT DECREASE P-TAU AND IMPROVE COGNITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-10-10 | — | — | US | disclosed |
| EP-3510029-A1 | ALLOSTERIC CORTICOTROPIN-RELEASING FACTOR RECEPTOR 1 (CRFR1) ANTAGONISTS THAT DECREASE P-TAU AND IMPROVE COGNITION | The Regents of The University of California (US) | 2019-07-17 | — | — | EP | disclosed |
| WO-2018048953-A1 | ALLOSTERIC CORTICOTROPIN-RELEASING FACTOR RECEPTOR 1 (CRFR1) ANTAGONISTS THAT DECREASE P-TAU AND IMPROVE COGNITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11077108-B2 | Allosteric corticotropin-releasing factor receptor 1 (CRFR1) antagonists that decrease p-tau and improve cognition | CRHR1, CRH, CRHR2 | L3MBTL1 4130/4885CYP1A2 3512/4885CYP2C19 2719/4885 |
| US-20190307747-A1 | ALLOSTERIC CORTICOTROPIN-RELEASING FACTOR RECEPTOR 1 (CRFR1) ANTAGONISTS THAT DECREASE P-TAU AND IMPROVE COGNITION | CRHR1, CRH, CRHR2 | L3MBTL1 3683/4885CYP1A2 4179/4885CYP2C19 3981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.